http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
-
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
-
Aeterna Zentaris (AEZS) Granted New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
-
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
-
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
-
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
-
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
-
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
-
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
-
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
-
Aeterna Zentaris (AEZS) Issues Update on Ongoing Pivotal Phase 3 DETECT-Trial
-
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
-
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
-
Aeterna Zentaris (AEZS) Expands Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs
-
Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs
-
Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs
-
Aeterna Zentaris (AEZS) Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
-
Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
-
Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
-
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
-
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
-
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
-
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
-
Aeterna Zentaris (AEZS) Issues Business Outlook and Outlines Pipeline Priorities
-
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
-
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
-
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
-
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
-
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
-
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
-
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
-
Aeterna Zentaris (AEZS) Appoints Giuliano La Fratta as CFO
-
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
-
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
-
Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
-
Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
-
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
-
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
-
Aeterna Zentaris (AEZS) Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
-
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
-
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
-
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
-
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
-
Aeterna Zentaris (AEZS) Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
-
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
-
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
